Evaluation of p16/Ki- 67 cytology as triage test for high-risk HPV-positive women in a “see and treat strategy”
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Although high risk human papilloma virus DNA (hr-HPV-DNA) test is the primary tool for cervical cancer screening, with visual inspection with acetic acid (VIA) serving as a triage test where Pap cytology is not available, the low intra-observer agreement associated with VIA means its reliability is limited and a more efficient test is still required. The aim of this study was to compare the performance of p16/Ki-67 cytology with VIA in the detection of cervical precancer and the feasibility as an alternative triage in the “ see and treat strategy” .
Methods
In a hospital-based cross-sectional study, we utilized stored provider-collected specimens from a previous study of women referred with cervical abnormalities to a tertiary hospital in Kisumu County, Kenya from February 2021 to November 2023. Specimens were tested with both Xpert and p16/ki-67 Immunostain. All hr-HPV positive women with cervical lesions were triaged using VIA and p16/Ki- 67 cytology. CIN2 or worse (≥CIN2) were defined as the clinical end points.
Results
The p16/ Ki- 67 Immunostaining showed a statistically significant higher sensitivity (84.6% vs. 59.0%%), specificity (44.0% vs. 62.0%), positive predictive value (28.2% vs. 28.8%) and negative predictive value (91.7% vs. 85.3%) compared to VIA examination.
Conclusion
The p16/Ki-67 immunostaining for the detection of ≥CIN2 has shown high sensitivity and high negative predictive value in our study, which is comparable to several previous findings; implying that the assay is superior to VIA in identifying ≥CIN2 and can serve as an alternative tool for triaging primary HPV-positive women in the current “see and treat” strategy.
